Effect of GLP‐1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes

Claire Lin; Natalie Braun; Sydney Corey; Beatrix B. Thompson; Kevin Sheng‐Kai; Steven T. Chen

doi:10.1111/jdv.70454

April 11, 2026Journal of the European Academy of Dermatology and Venereology

Effect of GLP‐1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the effects of GLP-1 receptor agonists on mortality and cardiovascular risk in individuals with psoriasis and type 2 diabetes.
Utilized data from TriNetX Research Network
Examined adult populations with psoriasis and type 2 diabetes
Analyzed mortality rates and cardiovascular outcomes
Findings indicate potential reductions in cardiovascular risk associated with GLP-1RA treatment
Results suggest lower mortality rates among treated individuals
Data support a favorable outcome for patients using GLP-1RA therapy

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational study examines cardiovascular risk and mortality in adults with psoriasis and type 2 diabetes, highlighting the potential benefits of GLP-1RA treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/69dc88b93afacbeac03ea879 https://doi.org/10.1111/jdv.70454

View at Publisher

Ask AI

Bookmark

Share

Effect of GLP‐1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Effect of GLP‐1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading